Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 6, 2014, Pages 321-329

  Togami, Kohei ^a   Hayashi, Yoshiaki ^a   Chono, Sumio ^a   Morimoto, Kazuhiro ^b  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Caco 2 cell monolayers; Clarithromycin; Intraportal administration; Oral bioavailability; Telithromycin

Indexed keywords

BROMSULFOPHTHALEIN; CLARITHROMYCIN; MULTIDRUG RESISTANCE PROTEIN; TELITHROMYCIN; VERAPAMIL; ANTIINFECTIVE AGENT; KETOLIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG TRANSPORT; ELIMINATION RATE CONSTANT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; INTRAPORTAL DRUG ADMINISTRATION; LIVER CLEARANCE; MONOTHERAPY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; ANIMAL; BIOAVAILABILITY; BLOOD; INTESTINE; INTESTINE ABSORPTION; LIVER; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CLARITHROMYCIN; HUMANS; INTESTINAL ABSORPTION; INTESTINES; KETOLIDES; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PERMEABILITY; RATS, WISTAR;

EID: 84922211802     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1900     Document Type: Article

References (31)

1. Kucukbasmaci O, Gonullu N, Aktas Z, Gurol D, Berkiten R. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int J Antimicrob Agents 2003; 22: 497-501. DOI: S092485790300150X
2. Miyashita N, Fukano H, Niki Y, Matsushima T. In vitro activity of telithromycin, a newketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48: 403-405. doi:10.1093/jac/48.3.403.
3. Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000; 44: 1381-1382. doi:10.1128/AAC.44.5.1381-1382.2000.
4. Yoshida H, Furuta T. Tissue penetration properties of macrolide antibiotics - comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats. Jpn J Antibiot 1999; 52: 497-503.
5. Yamazaki H, Roeder V, Vicat P, et al. Pharmacokinetic studies of telithromycin in mouse, rat and dog. Jpn J Chemother 2003; 51: 182-199.
6. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992; 36: 1147-1150. doi:10.1128/AAC.36.5.1147.
7. Perret C, Lenfant B, Weinling E, et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002; 48: 217-223. doi:10.1159/000066766.
8. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005; 43: 123-133.
9. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 2005; 25: 42-51. doi:10.1592/phco.25.1.42.55621.
10. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-2083. doi:10.1128/AAC.39.9.2078.
11. Li XM, Wang FC, Yang F, Jin YH. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials. Chin Med J 2013; 126: 2179-2185.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738.
13. Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 1995; 12: 1304-1310. doi:10.1023/A:1016217505990.
14. Padovan J, Ralic J, Letfus V, Milic A, Bencetic Mihaljevic V. Investigating the barriers to bioavailability of macrolide antibiotics in the rat. Eur J Drug Metab Pharmacokinet 2012; 37: 163-171. doi:10.1007/s13318-011-0074-5.
15. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 2009; 36: 580-590. doi:10.1016/j.ejps.2008.12.005.
16. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005; 25: 445-453. doi:10.1016/j.ejps.2005.04.003.
17. Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos 2011; 32: 389-397. doi:10.1002/bdd.767.
18. Togami K, Chono S, Seki T, Morimoto K. Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. Drug Metab Pharmacokinet 2009; 24: 411-417. doi:10.2133/dmpk.24.411.
19. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981; 4: 879-885.
20. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-558.
21. Tabata K, Yamaoka K, Yasui H, Fukuyama T, Nakagawa T. Influence of pentobarbitone on invivo local disposition of diclofenac in rat liver. J Pharm Pharmacol 1996; 48: 866-869. doi:10.1111/j.2042-7158.1996.tb03989.x.
22. Kato M, Chiba K, Hisaka A, et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 2003; 18: 365-372. doi:10.2133/dmpk.18.365.
23. Bramer SL, Au JL,Wientjes MG. Gastrointestinal and hepatic first-pass elimination of 2′,3′-dideoxyinosine in rats. J Pharmacol Exp Ther 1993; 265: 731-738.
24. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998; 42: 927-929.
25. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001; 296: 584-591.
26. Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001; 296: 723-735.
27. Saito H, Fukasawa Y, Otsubo Y, Yamada K, Sezaki H, Yamashita S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm Res 2000; 17: 761-765.
28. Pachot JI, Botham RP, Haegele KD, Hwang K. Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci 2003; 6: 1-12.
29. Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res 2001; 18: 1102-1109.
30. Togami K, Chono S, Morimoto K. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie 2012; 67: 389-393. doi:10.1691/ph.2012.1699.
31. Yamaguchi S, Zhao YL, Nadai M, et al. Involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006; 50: 80-87. doi:10.1128/AAC.50.1.80-87.2006.